Study: NCT02666287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT
Description: BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF (MgSt)
Description: FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/Vilanterol
Description: FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.